Market Place
Sourcing Support
Dupert Offers Hope As China`s First KRAS G12C Inhibitor For NSCLC
09 Sep 2024 //
EXPRESSPHARMA
GenFleet Announces First KRAS G12C Inhibitor Approval In China For NSCLC
23 Aug 2024 //
PR NEWSWIRE
Verastem Doses First Patient With GFH375/VS-7375 In China Phase 1/2 Trial
12 Jul 2024 //
BUSINESSWIRE
GenFleet Gets IND Approval For KRAS Inhibitor In Phase I/II Trial
19 Jun 2024 //
PR NEWSWIRE
GenFleet`s Fulzerasib Combo Shows Efficacy, Safety In Phase II NSCLC Trial
01 Jun 2024 //
PR NEWSWIRE
GenFleet`s GFH925 KRAS G12C Inhibitor Gets FDA Phase 3 CRC Approval
19 Apr 2024 //
PR NEWSWIRE
GenFleet: GFH547 PanRAS Inhibitor Activity Vs Resistance At AACR
09 Apr 2024 //
PR NEWSWIRE
GenFleet: GFH375 KRAS G12D Inhibitor Efficacy At AACR 2024
09 Apr 2024 //
PR NEWSWIRE
GenFleet Therapeutics Announces GFH009 Granted with FDA Fast Track
11 Jan 2024 //
PR NEWSWIRE
China`s First NDA for a KRAS G12C Inhibitor: NMPA Accepts NDA for GFH925
24 Nov 2023 //
PR NEWSWIRE
GenFleet Starts Phase Ib/II Trial of GFH009 (Highly Selective CDK9 Inhibitor)
10 Oct 2023 //
PR NEWSWIRE
Verastem Oncology Enters Discovery and Development Collaboration with GenFleet
28 Aug 2023 //
BUSINESSWIRE
2023 ASCO | Multi-center Data for Combination Study of GenFleet`s GFH018
06 Jun 2023 //
PR NEWSWIRE
GenFleet Therapeutics to Present Phase I Data for GFH312 at Meeting
09 Mar 2023 //
PR NEWSWIRE
GenFleet receives EMA approval for phase Ib/II study of GFH925 with ERBITUX
01 Mar 2023 //
PR NEWSWIRE
GenFleet & Merck Enter into Collaboration to Initiate Study Investigating GFH925
19 Dec 2022 //
PRNEWSWIRE
GenFleet Therapeutics to Present Data from Phase I Trial of GFH018 Monotherapy
07 Sep 2022 //
PRNEWSWIRE
GenFleet Receives FDA Approval for Phase II Study of RIPK1 Inhibitor (GFH312)
18 Aug 2022 //
PRNEWSWIRE
GenFleet Receives CTAs Approval for Two Phase II Combination Studies of GFH018
22 Jul 2022 //
PRNEWSWIRE
BioLineRx, GenFleet Enters Co-Development Agreement for Motixafortide in PDAC
29 Jun 2022 //
PRNEWSWIRE
BioLineRx Announces Collaboration Agreement with GenFleet Therapeutics in PDAC
28 Jun 2022 //
PRNEWSWIRE
GenFleet licenses KRAS candidate GFH925 to Innovent Biologics in China
02 Sep 2021 //
SEEKING ALPHA
Innovent & GenFleet deal for KRAS inhibitor; TCR2 receives FDA`s ODD on gavo-cel
02 Sep 2021 //
ENDPTS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.